Curis Lifesciences Ltd (CURIS) — shareholding pattern, promoter holding, financials and share price
About Curis Lifesciences Ltd (CURIS)
Curis Lifesciences Ltd operates in the Pharmaceuticals industry, within the Healthcare sector. It trades on the NSE as CURIS and on the BSE under scrip code 94348. Its ISIN is INE1BZN01016.
Incorporated in 2010, Curis Lifesciences Limited is a pharmaceutical company that specializes in developing, manufacturing, and distributing a diverse range of products. [1]
Curis Lifesciences Limited primarily manufactures pharmaceutical products, covering a diverse range of formulations including tablets, capsules, and ointments. Their core markets are Africa and Latin America, with a focus on contract manufacturing and direct exports.
The company has a strong export focus, with 63.78% of its turnover being international, and key markets including Nigeria and Kenya. Their strategic focus on exports supports higher profit margins.
Listed peers in Pharmaceuticals: Makers Laboratories Ltd, Amwill Health Care Ltd, Samrat Pharmachem Ltd, Zenith Drugs Ltd, Veerhealth Care Ltd, Bharat Immunological & Biological Corporation Ltd.
Valuation & Returns
10 Jul 2026At ₹100.7 a share on 10 Jul 2026, Curis Lifesciences Ltd (CURIS) was valued at a price-to-earnings ratio of 15.19x against an industry P/E of 36.41x and a price-to-book of 2.17x on a book value of ₹46.32 per share. Solomo computes return on equity of 21.8% and return on capital employed of 21.2% from filed results.
- P/E
- 15.19x
- Industry P/E
- 36.41x
- P/B
- 2.17x
- EPS (TTM)
- ₹6.63
- Book value / share
- ₹46.32
- ROE
- 21.8%
- ROCE
- 21.2%
- Debt / equity
- 2.45x
- Dividend yield
- 0%
- 52-week range
- ₹83.6 – ₹147.9
Ratios are computed from filed results and the last recorded price. Not investment advice.
Financial Performance
Mar 2024In the year ended Mar 2024, Curis Lifesciences Ltd (CURIS) reported revenue of ₹35.58 crore, net profit of ₹5.36 crore and earnings per share of ₹107.2. That compares with revenue of ₹35.42 crore and net profit of ₹1.23 crore in Mar 2023. Figures are consolidated, as filed with the exchanges.
In the quarter ended Jun 2024, revenue was ₹9.12 crore and net profit ₹1.2 crore (consolidated).
| Metric | Mar 2023 | Mar 2024 |
|---|---|---|
| Revenue (₹ cr) | 35.42 | 35.58 |
| Net profit (₹ cr) | 1.23 | 5.36 |
| EPS (₹) | 24.6 | 107.2 |
| Measure | 3Y | 1Y |
|---|---|---|
| Sales growth | 27.43% | 38.16% |
| Profit growth | 131.45% | 25.46% |
Ownership Summary
Mar 2026As of Mar 2026, promoters hold 68.03% of Curis Lifesciences Ltd (CURIS). Market capitalisation was ₹81 crore on 10 Jul 2026. Shareholding is filed quarterly with BSE and NSE; Solomo carries every filing back to Mar 2026.
Largest disclosed public shareholders in Mar 2026: `S S Corporate Securities Limited 2.81%, Strategic Sixth Sense Capital Fund 2.17%, Sachin Kapoor 2.04%, Sixth Sense Securities Private Limited 1.72%, Maiq Growth Scheme-Long Only 1.51%, Rs Wealth Management Private Limited 1.37%. Only stakes above the 1% disclosure threshold are named in filings.
| Quarter | Promoter | Pledged | FII | DII | Public |
|---|---|---|---|---|---|
| Mar 2026 | 68.03% | - | - | - | - |